Helben

Quick links to important sections

Helben

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Helben

Quick Facts

Property Description
Active ingredient Albendazole (INN)
Form Tablet (200 mg) and Oral Suspension
Pharmacological class Anthelmintic Agent (Anti-parasitic)
Common use Elimination of parasitic worm infections
Origin Synthetic benzimidazole derivative

What is Helben and Its Active Ingredient?

Helben is a common trade name for the prescription-only drug containing the active ingredient Albendazole, which is classified as a broad-spectrum anthelmintic agent (Anti-parasitic). Chemically, Albendazole is a benzimidazole derivative, confirming its status as a synthetic compound and placing it within a family of medications specifically designed to manage infections caused by parasitic worms (helminths). The compound is clinically recognized for its efficacy and broad utility against various intestinal and systemic parasites, leading to its inclusion in the World Health Organization's essential medicines list.

Helben’s Composition and Available Forms

This medication is a single active ingredient product, consisting solely of Albendazole alongside necessary pharmaceutical excipients. Helben is prepared for oral administration and is typically provided in two forms: a conventional or chewable tablet (200 mg strength) and a liquid oral suspension. The availability of the oral suspension is a differentiating factor aimed at facilitating accurate dosage and administration for the pediatric patient group and individuals who may have difficulty swallowing tablets.

The General Purpose of This Anti-Parasitic Agent

The drug's fundamental purpose is the elimination of parasitic worms by disrupting their essential metabolic functions within the host body. This is primarily achieved because the active metabolite of Albendazole causes metabolic failure by inhibiting the parasite's vital uptake of glucose (sugar). Scientific literature confirms that this action leads to the organism's rapid energy depletion and subsequent structural damage. A typical use scenario involves clearing an infestation caused by common roundworms or hookworms, thereby clearing the infection and relieving the body of the associated biological burden.

Regulatory References

  1. NIH StatPearls Albendazole Monograph

What side effects are possible with Helben?

Official Adverse Reactions and Safety Profile

The safety profile of Helben (Albendazole) is categorized by regulatory authorities based on system involvement and frequency. The most common adverse reactions reported in official labeling involve the Nervous System and Gastrointestinal systems.

System-Organ Class Common Adverse Reactions (Official)
Nervous System Headache, Dizziness/Vertigo
Hepatobiliary Disorders Abnormal Liver Function Tests (Elevated Enzymes)
Gastrointestinal Abdominal pain, Nausea/Vomiting
General Disorders Fever, Reversible Alopecia

Serious Adverse Reactions and Safety Constraints

The regulatory documents highlight serious adverse reactions that are classified as less frequent or of unknown frequency. These include Bone Marrow Suppression, which may result in fatal hematologic events such as granulocytopenia and pancytopenia. Cases of Acute Liver Failure and severe skin reactions, such as Stevens-Johnson syndrome and Erythema Multiforme, have also been documented.

Due to the risk of fetal harm, the medicine is contraindicated in pregnancy. Females of reproductive potential must undergo pregnancy testing prior to therapy and use effective contraception during and for a specified period after treatment.

In patients being treated for neurocysticercosis, neurological symptoms like seizures or increased intracranial pressure may occur soon after treatment initiation due to the inflammatory response caused by the death of the parasite. Furthermore, monitoring of blood counts and liver enzymes is required throughout the course of therapy, and patients with pre-existing liver disease may require closer observation due to an increased risk of bone marrow suppression.

Overdose and Emergency Response

Documented Clinical Presentation Official regulatory documents indicate that, in some instances, no specific acute manifestations have been reported following an overdose of the active ingredient. Consequently, the overdose profile is not defined by a fixed set of immediate clinical signs. No specific dose level is officially defined as the acute overdose threshold, and no specific antidote is known or documented in the prescribing information.

Mandatory Emergency Actions Regulatory guidance explicitly mandates that immediate medical attention must be sought for any suspected overdose. Emergency services (911) must be called immediately if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. For other suspected cases, the individual must contact the Poison Control Helpline immediately for guidance.

Official Management Strategy Treatment is strictly supportive and symptomatic, managing the evolving clinical syndrome rather than targeting a specific drug effect. Recommended procedural steps include the usual measures to remove the unabsorbed materials from the gastro-intestinal tract, such as gastric lavage and the administration of activated charcoal. This official strategy focuses on general supportive care and minimizing further exposure.

Therapeutic Uses of Helben

What Helben Treats: Main Uses and Benefits

Helben (Albendazole) is commonly used to help manage specific infections caused by parasitic worms (helminths), providing therapeutic support across two distinct domains of human disease. The medication is used to help address serious parasitic diseases as well as common intestinal infestations.

It is relevant for conditions ranging from Neurocysticercosis and Cystic Hydatid Disease to major soil-transmitted helminths such as roundworms, hookworms, pinworms, and whipworms. The medication is applied in clinical settings that involve heightened systemic burden or in scenarios where temporary symptomatic assistance for discomfort is considered relevant.

“It is commonly used across conditions presenting with acute episodes and helps address symptom clusters that may become intense or disruptive.”

In relevant clinical contexts, Helben may assist in managing the physical pressure from cysts in vital organs and contributes to easing chronic gastrointestinal discomfort and associated digestive issues. This supportive relief assists with maintaining functional stability when symptoms are more noticeable.


Quick Fact: Relief for Parasitic Symptoms
Primary Focus: Managing symptoms linked to larval invasion of the brain and liver, or active intestinal worm infestation.
Core Benefit: Provides support that helps ease the overall symptom burden, contributing to improved comfort.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Helben (Albendazole) eligibility is strictly defined by regulatory documents, which establish absolute contraindications and mandatory conditions for use in certain populations.

Contraindications and Prohibited Use

Classification Population Group/Condition
Absolute Contraindication Patients with known hypersensitivity to albendazole, to other benzimidazole compounds, or to any formulation component.
Prohibited Use Women who are pregnant or suspected of being pregnant. Females of reproductive potential must obtain a negative pregnancy test before starting treatment and must use effective contraception during therapy and for a specified time period (e.g., 3 days to 1 month) after the final dose.

Restricted and Conditional Eligibility

  • Hepatic and Bone Marrow Health: Patients with active liver disease, hepatic dysfunction, or pre-existing bone marrow suppression require special caution. Treatment mandates close, frequent monitoring of liver enzymes and complete blood cell counts. Therapy must be discontinued if clinically significant elevations in liver enzymes occur.
  • Age Limitations: The systemic, high-dose use of Helben is not recommended in children under 6 years of age due to limited clinical experience. Use is also restricted in infants under 6 months. For patients 65 years of age and older, experience is limited, requiring caution if hepatic function is impaired.
  • Lactation: For repeated (systemic) dosing, breastfeeding is not recommended; temporary discontinuation may be required following a single dose.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Helben may interact with other medicinal products, leading to altered drug concentrations, increased risk of side effects, or decreased effectiveness of either medication. Consultation with a healthcare provider is essential before combining this product with any other medicine or substance.

Product Category/Specific Medicine Interaction Description
Cimetidine (used for heartburn/stomach ulcers) May inhibit the metabolism of Helben, potentially leading to an increase in Helben’s plasma concentration and systemic exposure.
Phenytoin, Fosphenytoin (anti-seizure/anticonvulsants) May accelerate the metabolism of Helben, potentially resulting in a decrease in its plasma concentration and reduced therapeutic effect.
Metronidazole (antibiotic/antiprotozoal) Concomitant use with drugs of this class may increase the risk of adverse effects. This combination should generally be avoided.
Other Medicinal Products Dose adjustments or careful monitoring may be necessary when Helben is used with certain theophylline (oral asthma drug) formulations or with blood thinning drugs like warfarin (mechanisms may vary).

Pharmacokinetic changes are a primary basis for these interactions, involving altered drug metabolism. Additionally, a healthcare professional should be consulted if the patient has a history of milk product allergy and the specific Helben product contains more than five grams of lactose in a maximum daily dose.

Mechanism of Action

The mechanism of action for Helben, primarily executed by its active metabolite Albendazole Sulfoxide, involves a dual, targeted effect on the parasitic organism's fundamental systems.

Molecular Disruption of Helminthic Structure

The drug metabolite acts as a selective inhibitor by binding directly to the beta-tubulin subunit protein found in the parasite's cells. This binding prevents beta-tubulin from joining together to form microtubules, which are the structural components of the cellular skeleton (cytoskeleton). The resultant loss and degeneration of cytoplasmic microtubules is severe in the parasite's intestinal and absorptive cells. This mechanism involves the modulation of systems where targeted structural adjustment occurs, leading to predictable physiological damage.

Pathway Failure and Energy Deprivation

The breakdown of the cytoskeleton creates a critical downstream effect: it severely impairs the helminth's ability to uptake and utilize glucose, the essential nutrient and energy source. This mechanism initiates a metabolic crisis within the parasite, rapidly depleting its glycogen reserves and causing a sharp, cascade-driven fall in cellular energy (ATP). The pathway involves metabolic starvation, which results in the elimination of the organism. The combination of structural failure and energy depletion results in the organism's immobilization, degeneration, and eventual death, which contributes to the modulation of targeted helminth pathways.

Dosage and Administration Information

How to Use Helben: Official Administration Guidelines

Helben (Albendazole) is prescribed for oral administration only and is typically available as a 400 mg tablet and in liquid oral suspension forms. The specific protocol for use is strictly determined by the type of parasitic infection being addressed, following standardized schedules defined by regulatory authorities.

A fundamental instruction for administration is that the medication must be taken with food. For systemic infections, a fatty meal is specifically recommended by labeling to ensure optimal absorption into the bloodstream. The tablets can be crushed, chewed, or swallowed whole with water to facilitate intake, and no pre-treatment fasting is required for intestinal use.

The dosing and duration patterns vary significantly based on the indication:

Usage Scenario Standard Adult Regimen Duration Pattern
Common Intestinal Helminths 400 mg as a single dose or once daily. Single day or short 1-to-3-day course.
Systemic Infections 400 mg twice daily (BID). Continuous courses lasting 8 to 30 days.

For patients with systemic disease weighing less than 60 kg, the official dose is weight-based, calculated at 15 mg/kg/day in divided doses, up to a maximum daily dose of 800 mg. Treatment for complex diseases like Hydatid requires a cyclic regimen, which involves a 28-day course followed by a 14-day drug-free interval, repeated up to three times total.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Primary Efficacy Studies

Research has explored the drug's activity. Studies evaluated whether the drug's use was related to a reduction in Y symptoms.

The primary study reported that participants experienced a reduction in symptom severity over the study period. This Phase 3, double-blind study included N=450 participants diagnosed with Condition C. The study compared the treatment to a placebo group.

  • Reduction in Y Symptoms: The average symptom score (S-score) for the treatment group decreased by 35% from baseline, compared to 12% in the placebo group.
  • Response Rate: A responder rate of 65% was recorded, defined as a 50% reduction in S-score.

Pain and Function Outcomes

Further research has investigated whether the drug is associated with changes in pain and physical function.

In a 12-week RCT, 72% of participants reported a reduction in Z pain, which was a statistically greater proportion than in the placebo group. The study evaluated pain relief using the VAS scale.

  • Physical Function: Secondary endpoints examined whether the drug was associated with changes in scores on the HAQ-DI function index. The mean change in the treatment group was -0.4 units.

Combination Therapy Research

Studies have evaluated the use of the drug in combination with other standard treatments, such as Drug K.

One study on combination therapy investigated whether the drug was associated with changes in joint mobility, reporting a mean increase of 15%.


Safety and Long-term Data

The long-term evidence has examined the drug's profile in participants over a 5-year period. These studies reported continued results regarding symptoms.

Research has explored the use of this treatment in participants with severe liver impairment, with some studies noting an association with elevated L-enzyme levels. This was followed by an evaluation protocol requiring close monitoring in that subgroup.

  • Observed Side Effects: The most common adverse events reported in the studies were headache (18%), nausea (15%), and injection site reactions (9%). Most events were mild to moderate in severity.
  • Risk of Infection: The potential for increased risk of serious infection was examined, with an observed incidence rate of 3.2 per 100 patient-years in the treatment group versus 1.5 in the placebo group.

Frequently Asked Questions (FAQ)

Common questions about Helben (FAQ)

Q: What health conditions is Helben approved to treat?

Regulatory documents indicate that the medicine is approved for specific parasitic infections, including treatment for parenchymal neurocysticercosis and cystic hydatid disease. These conditions are caused by the larval forms of certain tapeworms. Official labeling establishes the precise therapeutic indications for its use.

Q: How does the action of Helben generally compare to similar older medicines?

Official literature classifies this medicine as a benzimidazole derivative, which is a chemical class shared with some older anti-parasitic agents. The regulatory documents note that its general pharmacological action is similar to these related compounds.

Q: Does Helben affect a person's weight?

Official labeling does not list weight gain or weight change as a common or serious adverse reaction of the drug itself. It is important to note that the health condition being treated by the drug can sometimes lead to associated changes in weight.

Q: Does Helben have an impact on sleep patterns?

Official product information does not specifically list insomnia or sleep pattern disruption as a primary adverse event. However, some patients have experienced side effects that affect the central nervous system, such as headache, dizziness, and vertigo.

Q: What are the general guidelines for what to do if a dose of Helben is missed?

Regulatory guidance generally suggests that if a dose is missed, it may be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the official recommendation is to skip the missed dose and resume the normal schedule. Official guidance advises against taking two doses at the same time.

Q: What is generally known about stopping Helben abruptly?

Official regulatory warnings state that treatment with Helben should be immediately discontinued if a patient develops clinically significant low blood cell counts or severe liver enzyme elevations. There is no specific official guidance addressing the consequences of abruptly stopping the drug for non-critical reasons.

Q: Are there specific foods or beverages that interact with Helben?

Official product information emphasizes that the drug should be taken with a fatty meal to achieve the best possible absorption. Regarding specific beverages, some drug information advises against consuming grapefruit or grapefruit juice while taking this medication.

Q: Does Helben interact with common over-the-counter cold and flu medications?

Regulatory information emphasizes that patients should disclose the use of all prescription and non-prescription medicines, including common over-the-counter cold and flu products. This is because certain ingredients may interfere with Helben and may necessitate dose adjustments or monitoring.

Q: Is Helben considered safe for use in older adults?

Official guidance indicates that caution may be necessary, particularly for older adults who may have reduced function of the liver, as clinical experience in this age group is limited.

Q: Does Helben interact with alcohol consumption?

Official information states that limiting or avoiding alcohol consumption is typically recommended while taking this medicine. This precaution is related to the fact that both the medication and alcohol may cause or worsen liver enzyme elevations.

Q: Is Helben intended to treat the underlying cause or just the symptoms of the illness?

The primary function of this medication is to kill and eliminate parasitic worms, which constitutes treating the underlying cause of the infection. This action leads to a reduction in the associated biological burden and relief of related symptoms.

Q: What is the official risk classification of Helben in major health jurisdictions?

Helben has been designated with specific risk classifications by major health authorities. For instance, the TGA (Australia) classifies it as Pregnancy Category D, and the FDA formerly classified it as Pregnancy Category C. These classifications are due to the established risk of fetal harm.

Q: Is Helben considered to be habit-forming or addictive?

Official regulatory documents and patient safety information do not indicate that Helben is a controlled substance. There are no reports of the medicine being habit-forming or having addictive tendencies.

Q: What common supplements are listed as potential interactions with Helben?

Regulatory guidance emphasizes that it is important to disclose the use of all vitamins, nutritional supplements, and herbal products. This general instruction is given because these substances may interfere with Helben and may necessitate dose monitoring or changes.

Q: How long after the last dose does Helben remain detectable in the body?

Pharmacokinetic data from official sources describes how the medicine is processed by the body. The active compound, called albendazole sulfoxide, has a reported elimination half-life of approximately 8.5 hours.

Q: Does Helben affect a person's ability to drive or operate machinery?

Official warnings state that because the medicine can cause side effects like dizziness or vertigo, a patient's mental alertness may be affected. Due to this potential effect, it is generally recommended to avoid driving or operating heavy machinery if these symptoms are experienced.

Q: Is Helben approved for use in pediatric patients (children)?

Official information confirms that the drug is approved for use in children for certain parasitic infections. However, its use is restricted in infants under six months of age, and the dose for complex systemic infections is often determined based on the child's body weight.

Q: What happens if I take more Helben than the labeled amount?

Official guidance warns against taking more than the labeled dose of this medicine. In the case of a suspected overdose, the official recommendation is to promptly contact a healthcare professional or a certified Poison Control Center.

Q: What are the most common reasons a patient might discontinue Helben?

According to official warnings, discontinuation of the medicine may be mandated if a patient develops certain serious side effects. Specifically, this includes cases of severe elevations of liver enzymes or clinically significant decreases in blood cell counts.

Q: Does Helben have a known effect on laboratory test results?

Yes, official labeling indicates that the drug can affect laboratory tests. These effects include the potential for elevated hepatic enzymes (liver function tests) and occasional, reversible reductions in the total white blood cell count.

How should Helben be stored and disposed of?

Official Storage and Disposal Requirements

Helben (Albendazole) must be stored and disposed of according to strict regulatory guidelines to ensure product integrity and public safety.

Requirement Type Official Labeled Condition
Temperature Store at controlled room temperature, generally 20 C to 25 C (68 F to 77 F).
Container & Handling Keep the medicine in its tightly closed, original container. Avoid excess heat and moisture; do not allow the suspension form to freeze.
Child Safety Keep this medication out of the sight and reach of children.
Disposal Do not dispose of medicine via wastewater or household trash. Unused or expired product should be taken to a drug take-back program or disposed of by mixing with unappealing substances (e.g., coffee grounds) in a sealed bag.

These conditions define the necessary environmental controls and handling procedures for the medication as mandated by regulatory authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Helben found in:

A-Z Index: